Hematology focuses on diseases of the blood, bone marrow, and lymphatic system. Learn about the diagnosis and treatment of anemia, leukemia, and lymphoma.
Send us all your questions or requests, and our expert team will assist you.
Diagnosis and evaluation are the cornerstones of effective management for individuals living with sickle cell anemia. Whether you are a patient seeking care abroad or a caregiver coordinating treatment, understanding the diagnostic pathway ensures timely intervention and optimal outcomes. In the United States and Europe, more than 100,000 people are affected by this hereditary blood disorder, and early detection can reduce life‑threatening complications by up to 30 %.
This page is designed for international patients who are considering treatment at Liv Hospital in Istanbul. It outlines the step‑by‑step process used by our hematology team, from initial laboratory screening to advanced imaging and long‑term monitoring. By the end of this guide, you will know what tests to expect, how disease severity is assessed, and how our multidisciplinary approach supports seamless, high‑quality care throughout your journey.
Our JCI‑accredited facilities combine cutting‑edge technology with a dedicated international patient services team, ensuring that every aspect of your diagnosis and evaluation is handled with expertise, compassion, and cultural sensitivity.
Sickle cell anemia is an inherited hemoglobinopathy caused by a mutation in the beta‑globin gene. This single‑point mutation leads to the production of abnormal hemoglobin S, which polymerizes under low‑oxygen conditions, distorting red blood cells into a sickle shape. These rigid cells can obstruct microvasculature, triggering painful crises and organ damage.
Accurate diagnosis and evaluation enable clinicians to differentiate sickle cell disease from other hemoglobin disorders, initiate disease‑modifying therapies, and plan preventive strategies. Early identification is especially critical for newborns, as prophylactic antibiotics and vaccinations can dramatically reduce infection‑related mortality.
By integrating these findings, our specialists create a comprehensive profile that guides treatment decisions from the outset.
Laboratory investigations form the backbone of the diagnostic work‑up. At Liv Hospital, we employ a tiered testing algorithm that begins with a complete blood count (CBC) and progresses to specialized hemoglobin studies.
The CBC provides a quick snapshot of hematologic health. Typical findings in sickle cell anemia include:
These techniques separate hemoglobin fractions, quantifying HbS, HbF, and HbA2. A result showing > 90 % HbS confirms homozygous sickle cell disease, while the presence of HbF can influence disease severity.
Polymerase chain reaction (PCR) and next‑generation sequencing (NGS) identify the β‑S mutation and any co‑inherited modifiers, such as α‑thalassemia, which may affect clinical presentation.
Additional labs used during evaluation include:
Our laboratory team follows international quality standards, ensuring that each result is reliable and reproducible for precise diagnosis and evaluation.
While blood tests confirm the presence of sickle cell disease, imaging studies are essential for detecting organ involvement and guiding therapeutic interventions.
Transcranial Doppler (TCD) ultrasound evaluates cerebral blood flow velocity, identifying children at high risk for stroke. Abdominal ultrasound monitors liver size, gallbladder disease, and splenic sequestration.
MRI, especially with T2* sequences, detects silent cerebral infarcts and quantifies iron overload in the heart and liver. Whole‑body MRI can reveal musculoskeletal complications such as avascular necrosis.
Chest X‑ray is the first line for acute chest syndrome, while CT provides detailed assessment of pulmonary emboli or chronic lung changes.
By integrating imaging findings with laboratory data, our multidisciplinary team delivers a thorough diagnosis and evaluation that informs personalized care plans.
Beyond confirming the diagnosis, evaluating disease severity is vital for risk stratification and treatment selection. Several scoring systems and biomarkers are routinely employed at Liv Hospital.
Regular assessments focus on the most vulnerable organs:
Complication screening is scheduled based on age and prior history, ensuring early detection and prompt intervention.
Through systematic diagnosis and evaluation, we can tailor disease‑modifying therapies such as hydroxyurea, L‑glutamine, or gene‑editing trials to each patient’s unique risk profile.
Once a definitive diagnosis is established, lifelong monitoring becomes the cornerstone of care. Our follow‑up protocol balances thoroughness with patient convenience, especially for international travelers.
Research at Liv Hospital incorporates novel markers such as soluble vascular cell adhesion molecule‑1 (sVCAM‑1) and circulating micro‑RNAs to predict vaso‑occlusive episodes before they manifest.
For patients residing abroad, we provide secure video consultations, electronic health record access, and coordinated local lab testing, ensuring continuity of care without unnecessary travel.
These structured follow‑up pathways exemplify a proactive diagnosis and evaluation philosophy that emphasizes prevention, early intervention, and sustained quality of life.
Choosing Liv Hospital for your sickle cell anemia management involves several coordinated steps. Our international patient services team guides you from the moment you contact us until you return home.
Our comprehensive approach ensures that every aspect of your diagnosis and evaluation journey is seamless, allowing you to focus on recovery and long‑term health.
Liv Hospital combines JCI accreditation, a multidisciplinary hematology team, and state‑of‑the‑art facilities to deliver world‑class care for sickle cell anemia. International patients benefit from dedicated coordinators who manage appointments, travel logistics, and language support, ensuring a stress‑free experience. Our commitment to evidence‑based medicine, combined with cutting‑edge therapies such as gene‑editing trials, positions us as a trusted partner for patients seeking comprehensive diagnosis and evaluation abroad.
Ready to take the next step in your care journey? Contact Liv Hospital today to schedule your personalized consultation and experience seamless, high‑quality diagnosis and evaluation in Istanbul.
Send us all your questions or requests, and our expert team will assist you.
The first step is a complete blood count (CBC) that often shows low hemoglobin, high reticulocyte count, and microcytosis. Hemoglobin electrophoresis or HPLC quantifies HbS, confirming sickle cell disease when >90 % HbS is present. A peripheral blood smear visualizes sickled and target cells. Genetic testing, such as PCR or next‑generation sequencing, identifies the specific β‑S mutation and any co‑inherited modifiers like α‑thalassemia. Together these tests create a comprehensive diagnostic profile that guides treatment decisions.
Liv Hospital applies the SCORMA Index, which combines clinical events, organ damage, and laboratory data into a single score. The frequency of painful vaso‑occlusive crises per year is recorded, providing a practical measure of disease burden. Hemoglobin F (HbF) levels are also measured, as higher HbF often correlates with milder disease. Additional organ‑specific assessments—including renal function (eGFR, proteinuria), cardiac imaging, and neurocognitive testing—are performed regularly to detect early complications. This multidimensional approach enables personalized treatment planning, including decisions about hydroxyurea, L‑glutamine, or enrollment in gene‑editing trials.
Transcranial Doppler (TCD) ultrasound screens children for elevated cerebral blood flow velocities, identifying high stroke risk. MRI, especially T2* sequences, quantifies iron overload in the heart and liver and detects silent cerebral infarcts. Whole‑body MRI can reveal musculoskeletal issues like avascular necrosis. Chest radiography is the first line for acute chest syndrome, while CT provides detailed evaluation of pulmonary emboli or chronic lung disease. These modalities are integrated with laboratory data to form a complete picture of organ involvement and guide therapeutic interventions.
After the initial diagnostic work‑up, Liv Hospital recommends a structured follow‑up schedule. Every three months patients undergo a CBC, reticulocyte count, and symptom review. Every six months liver and renal panels, ferritin, and HbF measurements are performed. Annually, patients receive a transcranial Doppler study, MRI (if indicated), and a full cardiopulmonary evaluation. For those living abroad, telemedicine consultations and local laboratory coordination ensure continuity of care without unnecessary travel. This proactive schedule helps detect complications early and adjust therapy promptly.
BlogHematologyFeb 19, 2026A complete blood count is a common test to check overall health. It helps find issues like anemia, infectio...
BlogHematologyFeb 19, 2026Thin blood, also known as thrombocytopenia, happens when you have too few platelets. Platelets help your bl...
BlogHematologyFeb 19, 2026Hemophilia is a genetic disorder that makes it hard for the body to form blood clots. It affects people all...
BlogAnemiaFeb 19, 2026Are you always tired, dizzy, or have brittle nails? Poor iron absorption might be the reason. It’s a ...
BlogHematologyFeb 19, 2026The Rule of Three is key in hematology. It helps labs check if a complete blood count (CBC) is right. It sa...
Get instant answers from our medical team. No forms, no waiting — just tap below to start chatting now.
Start Chat on WhatsApp or call us at +90 530 510 71 24
